JACOBIO-B (01167): KRAS G12C and SHP2 Combination Therapy Data Published in The Lancet Respiratory Medicine

Stock News12-01

JACOBIO-B (01167) announced that the Phase I/IIa clinical trial results of its self-developed KRAS G12C inhibitor glecirasib combined with SHP2 inhibitor JAB-3312 (sitneprotafib) have been officially published in the internationally renowned medical journal The Lancet Respiratory Medicine (impact factor: 32.8). This marks the first time globally that systematic clinical data on a dual oral small-molecule combination therapy targeting KRAS G12C and SHP2 has been featured in this authoritative journal.

The open-label Phase 1/2a study, conducted in China, enrolled 171 patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), including 102 treatment-naïve patients who had not previously received systemic therapy. Results showed that the combination therapy achieved a 71% objective response rate (ORR) and a median progression-free survival (mPFS) of 12.2 months in first-line patients, demonstrating leading efficacy among existing KRAS G12C-targeted first-line treatments. Compared to the current standard first-line treatment of immunotherapy plus chemotherapy, this chemotherapy-free alternative exhibits strong competitiveness.

Currently, the KRAS G12C inhibitor and SHP2 inhibitor are undergoing Phase III clinical trials in China, directly comparing this combination therapy with the existing standard treatment in first-line patients. The study aims to advance this dual oral combination as the world’s first potential SHP2-based combination therapy to gain regulatory approval.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139415594?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 07:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139415594","market":"nz","top_or_hot":-1,"title":"JACOBIO-B (01167): KRAS G12C and SHP2 Combination Therapy Data Published in The Lancet Respiratory Medicine","media":"Stock News","content":"<p>JACOBIO-B (01167) announced that the Phase I/IIa clinical trial results of its self-developed KRAS G12C inhibitor glecirasib combined with SHP2 inhibitor JAB-3312 (sitneprotafib) have been officially published in the internationally renowned medical journal The Lancet Respiratory Medicine (impact factor: 32.8). This marks the first time globally that systematic clinical data on a dual oral small-molecule combination therapy targeting KRAS G12C and SHP2 has been featured in this authoritative journal.</p>\n<p>The open-label Phase 1/2a study, conducted in China, enrolled 171 patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), including 102 treatment-naïve patients who had not previously received systemic therapy. Results showed that the combination therapy achieved a 71% objective response rate (ORR) and a median progression-free survival (mPFS) of 12.2 months in first-line patients, demonstrating leading efficacy among existing KRAS G12C-targeted first-line treatments. Compared to the current standard first-line treatment of immunotherapy plus chemotherapy, this chemotherapy-free alternative exhibits strong competitiveness.</p>\n<p>Currently, the KRAS G12C inhibitor and SHP2 inhibitor are undergoing Phase III clinical trials in China, directly comparing this combination therapy with the existing standard treatment in first-line patients. The study aims to advance this dual oral combination as the world’s first potential SHP2-based combination therapy to gain regulatory approval.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JACOBIO-B (01167): KRAS G12C and SHP2 Combination Therapy Data Published in The Lancet Respiratory Medicine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJACOBIO-B (01167): KRAS G12C and SHP2 Combination Therapy Data Published in The Lancet Respiratory Medicine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-01 07:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JACOBIO-B (01167) announced that the Phase I/IIa clinical trial results of its self-developed KRAS G12C inhibitor glecirasib combined with SHP2 inhibitor JAB-3312 (sitneprotafib) have been officially published in the internationally renowned medical journal The Lancet Respiratory Medicine (impact factor: 32.8). This marks the first time globally that systematic clinical data on a dual oral small-molecule combination therapy targeting KRAS G12C and SHP2 has been featured in this authoritative journal.</p>\n<p>The open-label Phase 1/2a study, conducted in China, enrolled 171 patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), including 102 treatment-naïve patients who had not previously received systemic therapy. Results showed that the combination therapy achieved a 71% objective response rate (ORR) and a median progression-free survival (mPFS) of 12.2 months in first-line patients, demonstrating leading efficacy among existing KRAS G12C-targeted first-line treatments. Compared to the current standard first-line treatment of immunotherapy plus chemotherapy, this chemotherapy-free alternative exhibits strong competitiveness.</p>\n<p>Currently, the KRAS G12C inhibitor and SHP2 inhibitor are undergoing Phase III clinical trials in China, directly comparing this combination therapy with the existing standard treatment in first-line patients. The study aims to advance this dual oral combination as the world’s first potential SHP2-based combination therapy to gain regulatory approval.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01167","symbol_name":"加科思-B","start_time":0,"source_url":"","article_id":"1139415594","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139415594","pubTimestamp":1764546619,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JACOBIO-B (01167) announced that the Phase I/IIa clinical trial results of its self-developed KRAS G12C inhibitor glecirasib combined with SHP2 inhibitor JAB-3312 (sitneprotafib) have been officially...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01167":"加科思-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"JACOBIO-B（01167）：KRAS G12C和SHP2联合治疗数据发表于《柳叶刀呼吸医学》","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":1},"content_text":"JACOBIO-B (01167) announced that the Phase I/IIa clinical trial results of its self-developed KRAS G12C inhibitor glecirasib combined with SHP2 inhibitor JAB-3312 (sitneprotafib) have been officially published in the internationally renowned medical journal The Lancet Respiratory Medicine (impact factor: 32.8). This marks the first time globally that systematic clinical data on a dual oral small-molecule combination therapy targeting KRAS G12C and SHP2 has been featured in this authoritative journal.\nThe open-label Phase 1/2a study, conducted in China, enrolled 171 patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), including 102 treatment-naïve patients who had not previously received systemic therapy. Results showed that the combination therapy achieved a 71% objective response rate (ORR) and a median progression-free survival (mPFS) of 12.2 months in first-line patients, demonstrating leading efficacy among existing KRAS G12C-targeted first-line treatments. Compared to the current standard first-line treatment of immunotherapy plus chemotherapy, this chemotherapy-free alternative exhibits strong competitiveness.\nCurrently, the KRAS G12C inhibitor and SHP2 inhibitor are undergoing Phase III clinical trials in China, directly comparing this combination therapy with the existing standard treatment in first-line patients. The study aims to advance this dual oral combination as the world’s first potential SHP2-based combination therapy to gain regulatory approval.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139415594","isCrawlerRequest":true}